Propanc Biopharma, Inc. (PPCB)
| Market Cap | 1.94M +1,706.4% |
| Revenue (ttm) | n/a |
| Net Income | -67.00M |
| EPS | -6.45 |
| Shares Out | 20.90M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 474,684 |
| Open | 0.0900 |
| Previous Close | 0.0905 |
| Day's Range | 0.0900 - 0.0950 |
| 52-Week Range | 0.0855 - 10.8100 |
| Beta | 3.40 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 18, 2026 |
About PPCB
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the research activities for the POP1 Program and the Un... [Read more]
Financial Performance
Financial StatementsNews
Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
MELBOURNE, Australia , May 13, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chro...
Propanc Biopharma files to sell 15M shares of common stock for holders
17:32 EDT Propanc Biopharma (PPCB) files to sell 15M shares of common stock for holders
Propanc Biopharma signs multi-year collaboration with Spanish universities
Propanc Biopharma (PPCB) announced that a multi-year joint research collaboration agreement has been established with the Universities of Jaen and Granada, Spain. “As we enter an exciting phase for th...
Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain
The goal is to strengthen our intellectual property and to better understand how PRP technology can overcome resistant tumors and age-related diseases.
Propanc Biopharma announces highlights of PRP
Propanc Biopharma (PPCB) announced highlights of PRP, its lead proenzyme therapy. The company said, “Conventional chemo hits walls of resistance, brutal toxicity, and minimal progress. PRP changes the...
Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy
MELBOURNE, Australia, March 12, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chr...
Propanc Biopharma executes service agreement with FyoniBio
Propanc Biopharma (PPCB) announced that management has executed a service agreement with FyoniBio, a German Contract Development Organization, CDO, based in Berlin for establishing and validating a li...
Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study
The purpose of the study will be used as an important tool to measure the concentration of PRP and its analytes over time upon administration to patients
Propanc Biopharma highlights potential of lead asset PRP
Propanc Biopharma (PPCB) highlights the potential of its lead asset, PRP, as a novel therapeutic approach to the treatment and prevention of metastatic cancer from solid tumors, especially more aggres...
Propanc Biopharma's Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models
MELBOURNE, Australia, March 03, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chr...
Propanc Biopharma provides corporate update
Propanc Biopharma (PPCB) announced an update on corporate progress as of December 31, 2025. Corporate and R&D Highlights: Accelerates IP Momentum: Files Four Provisional Patent Applications – Strength...
Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results
We are pleased with advancements made with our R&D programs and
Propanc Biopharma highlights potential of lead proenzyme therapy
Propanc Biopharma (PPCB) highlighted the potential of its lead proenzyme therapy, PRP, as a novel approach that could compete with existing approved therapies for solid tumors, particularly in areas o...
Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market
As we advance toward human trials, we remain committed to delivering hope to patients facing limited options for aggressive cancers from solid tumors.
Propanc Biopharma files to sell 7M shares of common stock for holders
17:32 EST Propanc Biopharma (PPCB) files to sell 7M shares of common stock for holders
Propanc Biopharma files fourth patent application with IP Australia
Propanc Biopharma (PPCB) announced the filing of its fourth new provisional patent application in the past two months with IP Australia. This latest application focuses on formulations of the pancreat...
Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations
MELBOURNE, Australia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chro...
Propanc Biopharma files new provisional patent application with IP Australia
Propanc Biopharma (PPCB) announced that a new provisional patent application has been filed for methods of producing trypinsogen and chymotrypsinogen with IP Australia. The patent application describe...
Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia
MELBOURNE, , Jan. 20, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic disea...
Propanc Biopharma announces update on pancreatic cancer research
Propanc Biopharma (PPCB) announced the latest update on pancreatic cancer research. Pancreatic cancer remains one of the most lethal human malignancies: median survival after diagnosis is typically me...
Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer
This high unmet need has drawn interest to novel mechanisms of action — including Propanc Biopharma's pancreatic proenzyme formulation known as PRP.
Propanc Biopharma issues letter to shareholders
Propanc Biopharma (PPCB) announced a shareholder update from its Chief Executive Officer and Cofounder, James Nathanielsz. “I am delighted to share an update on our recent achievements and to outline…
Propanc Biopharma Provides Shareholder Update
MELBOURNE, Australia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chro...
Propanc Biopharma publishes impact of proenzymes on PDAC fibroblasts
Propanc Biopharma (PPCB) announced that the Company and its joint research partners at the Universities of Jaen and Granada published key findings in a peer reviewed journal, Scientific Reports, regar...
Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal
MELBOURNE, Australia, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for chronic disease...